GLP-1受體促效劑市場：按藥物類型、品牌、應用、給藥途徑、類型、性別、年齡層、分銷管道和地區分類

預計到 2026 年，GLP-1 受體促效劑市場規模將達到 590.1 億美元，到 2033 年將達到 1,172.1 億美元。預計從 2026 年到 2033 年，該市場將以 10.3% 的複合年成長率成長。

GLP-1受體促效劑市場是糖尿病治療領域的一個創新細分市場，從根本上改變了第2型糖尿病和肥胖症的治療模式。 GLP-1類似物是天然存在的腸促胰島素激素GLP-1的合成版本，透過促進胰島素分泌、抑制升糖素釋放和延緩排放，在維持血糖穩態方面發揮至關重要的作用。這些創新療法因其雙重作用機製而成為基礎治療方法，既能有效控制血糖，又能顯著減輕體重。

該市場涵蓋多種製劑，包括每日一次、每週一次以及新興的長效製劑，以滿足不同患者的偏好和治療方案。領先企業已投入大量資金進行研發，旨在透過先進的給藥系統提高藥物療效、減少副作用並改善患者依從性。隨著全球糖尿病盛行率的上升以及人們對肥胖相關併發症認知的不斷提高，GLP-1類似物已成為醫療專業人員的首選治療方案。在降低心血管風險和潛在的神經保護作用等臨床應用不斷擴展的推動下，該細分市場持續強勁成長，使其成為現代製藥業中最具活力且發展最快的領域之一。

市場動態

GLP-1受體促效劑市場受多種強勁因素驅動，呈現穩健成長態勢。其中最主要的促進因素是全球第2型糖尿病和肥胖症盛行率的激增，目前全球有超過5.37億成年人患有糖尿病，這使得對有效治療性介入的需求空前高漲。 GLP-1類似物因其卓越的療效，已成為優於傳統糖尿病藥物的首選治療方案，不僅能顯著降低糖化血紅蛋白（HbA1c）水平，還能顯著減輕體重。此外，越來越多的臨床證據表明其具有心血管保護作用，並有望應用於非酒精性脂肪肝病（NAFLD）的治療，進一步拓寬了治療範圍，並提升了市場滲透率。藥物遞送系統的技術進步，例如緩釋製劑和創新注射裝置，透過提高患者的用藥便利性和依從性，進一步推動了市場成長。然而，該市場也存在一些限制因素。主要原因是GLP-1類似物的價格高於傳統糖尿病藥物，這構成了准入壁壘，尤其是在價格敏感型市場，並且在某些地區限制了其醫療覆蓋範圍。

胃腸道副作用，如噁心、嘔吐和腹瀉，會影響患者的藥物順從性和治療的持續性，可能阻礙市場滲透。胜肽類生技藥品的生產複雜性帶來了供應鏈挑戰和成本影響。然而，開發中國家的糖尿病盛行率正在迅速上升，加上醫療基礎設施的改善和保險覆蓋範圍的擴大，蘊藏著巨大的發展機會。 GLP-1類似物與其他糖尿病藥物聯合治療的潛力為市場開發提供了盈利空間。此外，針對阿茲海默症、帕金森氏症和其他代謝性疾病等新適應症的持續研究將顯著擴大目標市場，並有可能使GLP-1類似物成為糖尿病治療之外的多功能治療平台。

本次調查的主要特點

• 本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
• 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
• 本研究根據以下參數，介紹了全球Glucagon-Like Peptide-1 (GLP-1) 類似物市場的主要公司概況：公司亮點、產品系列、主要亮點、財務表現和策略。
• 透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
• 這份全球類升糖素肽-1類似物市場報告針對該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要

第3章：市場動態、監管與趨勢分析

• 市場動態
• 促進因素
• 抑制因子
• 機會
• 影響分析
• 主要進展
• 監管趨勢
• 產品上市及核准
• PEST分析
• 波特的分析
• 併購情景
• 產業趨勢

第4章：GLP-1受體促效劑市場：依藥物類型分類，2021-2033年

• Semaglutide
• Liraglutide
• Exenatide
• Dulaglutide
• 蒂爾澤帕蒂德
• 其他

第5章：GLP-1受體促效劑市場：依品牌分類，2021-2033年

• 薩克森達
• 維克托扎
• 奧贊皮克
• Wegovy
• Rybelsus
• Trulicity Pen
• Zepbound
• Mounjaro
• BYDUREON BCise
• 其他

第6章：GLP-1受體促效劑市場：依應用領域分類，2021-2033年

• 2型糖尿病
• 體重管理（肥胖/超重）
• 降低心血管風險

第7章 GLP-1受體促效劑市場：依給藥途徑分類，2021-2033年

• 口服
• 腸外

第8章：GLP-1受體促效劑市場：按類型分類，2021-2033年

• 品牌
• 非專利的

第9章：GLP-1受體促效劑市場：依性別分類，2021-2033年

• 男性
• 女士

第10章：GLP-1受體促效劑市場：依年齡層別分類，2021-2033年

• 成人
• 兒童

第11章 GLP-1受體促效劑市場：依通路分類，2021-2033年

• 醫院藥房
• 零售藥房
• 網路藥房

第12章 全球GLP-1受體促效劑市場：依地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲國家
• 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太國家
• 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東國家
• 非洲
  • 南非
  • 北非
  • 中非

第13章 競爭格局

• Novo Nordisk
• Eli Lilly and Company
• Sanofi
• AstraZeneca
• Boehringer Ingelheim
• Merck & Co.
• Amgen
• GlaxoSmithKline
• Bristol-Myers Squibb
• Takeda Pharmaceutical Company
• Daiichi Sankyo
• Pfizer
• Teva Pharmaceutical Industries
• Regeneron Pharmaceuticals
• Intarcia Therapeutics
• Hngzhou Jiuyuan Gene Engineering Co Ltd

第14章 分析師建議

• 機會分析
• 分析師意見
• Coherent Opportunity Map

第15章 參考文獻與調查方法

• 參考
• 調查方法
• 關於本公司

Glucagon Like Peptide 1 Analogs Market is estimated to be valued at USD 59.01 Bn in 2026 and is expected to reach USD 117.21 Bn by 2033, growing at a compound annual growth rate (CAGR) of 10.3% from 2026 to 2033.

The glucagon like peptide 1 analogs market represents a revolutionary segment within the diabetes therapeutics landscape, fundamentally transforming treatment paradigms for Type 2 diabetes mellitus and obesity management. GLP-1 analogs are synthetic versions of the naturally occurring incretin hormone GLP-1, which plays a crucial role in glucose homeostasis by stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying. These innovative therapeutic agents have emerged as cornerstone treatments due to their dual mechanism of action, offering both glycemic control and significant weight reduction benefits.

The market encompasses various formulations including once-daily, once-weekly, and emerging longer-acting preparations, catering to diverse patient preferences and treatment protocols. Leading pharmaceutical companies have invested heavily in research and development to enhance drug efficacy, reduce side effects, and improve patient compliance through advanced delivery systems. The growing prevalence of diabetes worldwide, coupled with increasing awareness of obesity-related comorbidities, has positioned GLP-1 analogs as preferred therapeutic options among healthcare providers. This market segment continues to witness robust growth driven by expanding clinical applications, including cardiovascular risk reduction and potential neuroprotective effects, making it one of the most dynamic and rapidly evolving sectors in modern pharmaceutical industry.

Market Dynamics

The glucagon like peptide 1 analogs market is propelled by several compelling drivers that underscore its robust growth trajectory. The primary driver is the escalating global prevalence of Type 2 diabetes and obesity, with over 537 million adults currently living with diabetes worldwide, creating an unprecedented demand for effective therapeutic interventions. The superior efficacy profile of GLP-1 analogs, demonstrating significant HbA1c reduction alongside substantial weight loss benefits, positions these agents as preferred treatment options over traditional diabetes medications. Additionally, expanding clinical evidence supporting cardiovascular protective effects and potential applications in non-alcoholic fatty liver disease (NAFLD) broadens the therapeutic scope, driving market adoption. Technological advancements in drug delivery systems, including extended-release formulations and innovative injection devices, enhance patient convenience and adherence, further stimulating market growth. However, the market faces notable restraints, primarily the high cost of GLP-1 analogs compared to conventional diabetes treatments, creating accessibility barriers particularly in price-sensitive markets and limiting insurance coverage in certain regions.

Gastrointestinal side effects, including nausea, vomiting, and diarrhea, can impact patient compliance and treatment continuation, potentially hindering market penetration. Manufacturing complexities associated with peptide-based biologics pose supply chain challenges and cost implications. Nevertheless, significant opportunities emerge from untapped markets in developing economies where diabetes prevalence is rapidly increasing, coupled with improving healthcare infrastructure and expanding insurance coverage. The potential for combination therapies integrating GLP-1 analogs with other diabetes medications presents lucrative development opportunities. Furthermore, ongoing research into novel indications including Alzheimer's disease, Parkinson's disease, and other metabolic disorders could substantially expand the addressable market, positioning GLP-1 analogs as versatile therapeutic platforms beyond diabetes management.

Key Features of the Study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global glucagon like peptide 1 analogs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Novo Nordisk, Eli Lilly and Company, Sanofi, AstraZeneca, Boehringer Ingelheim, Merck & Co., Amgen, GlaxoSmithKline, Bristol-Myers Squibb, Takeda Pharmaceutical Company, Daiichi Sankyo, Pfizer, Teva Pharmaceutical Industries, Regeneron Pharmaceuticals, Intarcia Therapeutics, and Hngzhou Jiuyuan Gene Engineering Co Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global glucagon like peptide 1 analogs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.

Market Segmentation

• Drug Type Insights (Revenue, USD Bn, 2021 - 2033)
• Semaglutide
• Liraglutide
• Exenatide
• Dulaglutide
• Tirzepatide
• Others
• Linagliptin
• Lixisenatide
• Brand Insights (Revenue, USD Bn, 2021 - 2033)
• Saxenda
• Victoza
• Ozempic
• Wegovy
• Rybelsus
• Trulicity Pen
• Zepbound
• Mounjaro
• BYDUREON BCise
• Others
• Application Insights (Revenue, USD Bn, 2021 - 2033)
• Type 2 Diabetes Mellitus
• Weight Management (Obesity/Overweight)
• Cardiovascular Risk Reduction
• Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
• Oral
• Parenteral
• Type Insights (Revenue, USD Bn, 2021 - 2033)
• Brand
• Generic
• Gender Insights (Revenue, USD Bn, 2021 - 2033)
• Male
• Female
• Age Group Insights (Revenue, USD Bn, 2021 - 2033)
• Adult
• Pediatric/Children
• Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
• Novo Nordisk
• Eli Lilly and Company
• Sanofi
• AstraZeneca
• Boehringer Ingelheim
• Merck & Co.
• Amgen
• GlaxoSmithKline
• Bristol-Myers Squibb
• Takeda Pharmaceutical Company
• Daiichi Sankyo
• Pfizer
• Teva Pharmaceutical Industries
• Regeneron Pharmaceuticals
• Intarcia Therapeutics
• Hngzhou Jiuyuan Gene Engineering Co Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Glucagon Like Peptide 1 Analogs Market, By Drug Type
  • Glucagon Like Peptide 1 Analogs Market, By Brand
  • Glucagon Like Peptide 1 Analogs Market, By Application
  • Glucagon Like Peptide 1 Analogs Market, By Route of Administration
  • Glucagon Like Peptide 1 Analogs Market, By Type
  • Glucagon Like Peptide 1 Analogs Market, By Gender
  • Glucagon Like Peptide 1 Analogs Market, By Age Group
  • Glucagon Like Peptide 1 Analogs Market, By Distribution Channel
  • Glucagon Like Peptide 1 Analogs Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Glucagon Like Peptide 1 Analogs Market, By Drug Type, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Semaglutide
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Liraglutide
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Exenatide
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Dulaglutide
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Tirzepatide
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Linagliptin
    • Lixisenatide

5. Glucagon Like Peptide 1 Analogs Market, By Brand, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Saxenda
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Victoza
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Ozempic
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Wegovy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Rybelsus
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Trulicity Pen
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Zepbound
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Mounjaro
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• BYDUREON BCise
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Glucagon Like Peptide 1 Analogs Market, By Application, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Type 2 Diabetes Mellitus
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Weight Management (Obesity/Overweight)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Cardiovascular Risk Reduction
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Glucagon Like Peptide 1 Analogs Market, By Route of Administration, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Parenteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

8. Glucagon Like Peptide 1 Analogs Market, By Type, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Brand
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Generic
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

9. Glucagon Like Peptide 1 Analogs Market, By Gender, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Male
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Female
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

10. Glucagon Like Peptide 1 Analogs Market, By Age Group, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Adult
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Pediatric/Children
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

11. Glucagon Like Peptide 1 Analogs Market, By Distribution Channel, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

12. Global Glucagon Like Peptide 1 Analogs Market, By Region, 2021 - 2033, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

13. Competitive Landscape

• Novo Nordisk
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Boehringer Ingelheim
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amgen
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Takeda Pharmaceutical Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Daiichi Sankyo
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Regeneron Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Intarcia Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Hngzhou Jiuyuan Gene Engineering Co Ltd
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

14. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

15. References and Research Methodology

• References
• Research Methodology
• About us